Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

被引：0
|
作者：
Vodanovic, Ivana Dora [1 ]
Nekic, Anja Barac [1 ]
Sambula, Lana [2 ]
Tomsic, Karin Zibar [1 ]
Dusek, Tina [1 ,3 ]
Kastelan, Darko [1 ,3 ]
机构：
[1] Univ Hosp Ctr Zagreb, Dept Endocrinol, Kispaticeva 12, Zagreb 10000, Croatia
[2] Gen Hosp Tomislav Bardek, Dept Nephrol Endocrinol & Diabetol, Koprivnica, Croatia
[3] Univ Zagreb, Sch Med, Zagreb, Croatia
来源：
ENDOCRINE RESEARCH | 2025年 / 50卷 / 01期
关键词：
Adjuvant treatment; adrenal insufficiency; adrenocortical carcinoma; adverse event; hydrocortisone replacement; mitotane; EUROPEAN NETWORK; PLASMA;
D O I：
10.1080/07435800.2024.2402311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BackgroundMitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.MethodsA retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.ResultsMitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.ConclusionCareful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
引用
收藏
页码：50 / 56
页数：7
相关论文
共 50 条
  • [1] Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
    Mormando, Marilda
    Galie, Edvina
    Bianchini, Marta
    Lauretta, Rosa
    Puliani, Giulia
    Tanzilli, Antonio
    Anceschi, Umberto
    Simone, Giuseppe
    Petreri, Gianluca
    Graziano, Giuliana
    Pace, Andrea
    Appetecchia, Marialuisa
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Mitotane treatment for adrenocortical carcinoma: an overview
    De Francia, S.
    Ardito, A.
    Daffara, F.
    Zaggia, B.
    Germano, A.
    Berruti, A.
    Di Carlo, F.
    MINERVA ENDOCRINOLOGICA, 2012, 37 (01) : 9 - 23
  • [3] Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
    Puglisi, Soraya
    Calabrese, Anna
    Basile, Vittoria
    Ceccato, Filippo
    Scaroni, Carla
    Simeoli, Chiara
    Torlontano, Massimo
    Cannavo, Salvatore
    Arnaldi, Giorgio
    Stigliano, Antonio
    Malandrino, Pasqualino
    Saba, Laura
    Altieri, Barbara
    Della Casa, Silvia
    Perotti, Paola
    Berchialla, Paola
    De Filpo, Giuseppina
    Canu, Letizia
    Loli, Paola
    Reimondo, Giuseppe
    Terzolo, Massimo
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [4] Practical treatment using mitotane for adrenocortical carcinoma
    Terzolo, Massimo
    Zaggia, Barbara
    Allasino, Barbara
    De Francia, Silvia
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (03) : 159 - 165
  • [5] What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
    Basile, Vittoria
    Puglisi, Soraya
    Altieri, Barbara
    Canu, Letizia
    Libe, Rossella
    Ceccato, Filippo
    Beuschlein, Felix
    Quinkler, Marcus
    Calabrese, Anna
    Perotti, Paola
    Berchialla, Paola
    Dischinger, Ulrich
    Megerle, Felix
    Baudin, Eric
    Bourdeau, Isabelle
    Lacroix, Andre
    Loli, Paola
    Berruti, Alfredo
    Kastelan, Darko
    Haak, Harm R.
    Fassnacht, Martin
    Terzolo, Massimo
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (04):
  • [6] Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
    Basile, Vittoria
    Puglisi, Soraya
    Calabrese, Anna
    Pia, Anna
    Perotti, Paola
    Berruti, Alfredo
    Reimondo, Giuseppe
    Terzolo, Massimo
    CANCERS, 2020, 12 (09) : 1 - 15
  • [7] Recovery of Adrenal Insufficiency is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
    Poirier, Jonathan
    Gagnon, Nadia
    Terzolo, Massimo
    Puglisi, Soraya
    El Ghorayeb, Nada
    Calabrese, Anna
    Lacroix, Andre
    Bourdeau, Isabelle
    CANCERS, 2020, 12 (03)
  • [8] New perspectives for mitotane treatment of adrenocortical carcinoma
    Puglisi, S.
    Calabrese, A.
    Basile, V
    Pia, A.
    Reimondo, G.
    Perotti, P.
    Terzolo, M.
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 34 (03)
  • [9] Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy
    Altieri, Barbara
    Lalli, Enzo
    Faggiano, Antongiulio
    MINERVA ENDOCRINOLOGY, 2022, 47 (02): : 203 - 214
  • [10] Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report
    Baszko-Blaszyk, Daria
    Ochmanska, Katarzyna
    Wasko, Ryszard
    Sowniski, Jerzy
    ENDOKRYNOLOGIA POLSKA, 2011, 62 (02) : 186 - 188
12345